Literature DB >> 25651421

T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.

Zhi-Zhang Yang1, Ai-Bin Liang2, Stephen M Ansell1.   

Abstract

The tumor microenvironment in B-cell non-Hodgkin lymphoma (NHL) comprises not only malignant cells but also significant numbers of normal immune cells. The intratumoral immune infiltrate includes T-lymphocytes that appear to target the malignant clone. Despite immunologically recognizing the lymphoma cells, the intratumoral T-cells are unable to eradicate the malignant cells and the lymphoma commonly progresses. Recent data has identified mechanisms whereby activated intratumoral T-cells are suppressed or become exhausted due to chronic antigen stimulation. A clearer understanding of these mechanisms will allow for strategies to overcome them and improve the outcome of patients with lymphoma.

Entities:  

Keywords:  Lymphoma; T cells; anti-tumour immunity

Mesh:

Substances:

Year:  2015        PMID: 25651421     DOI: 10.3109/10428194.2015.1011640

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond.

Authors:  Stephen M Ansell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Emerging role of checkpoint blockade therapy in lymphoma.

Authors:  Natalie Galanina; Justin Kline; Michael R Bishop
Journal:  Ther Adv Hematol       Date:  2017-01-22

4.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Authors:  Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2017-12-07       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.